Prospecto: Information for the Patient
Rizatriptan Teva 10 mg Bucodispersable Tablets EFG
Read this prospectus carefully before starting to take this medicine, as it contains important information for you - Keep this prospectus, as you may need to read it again. - If you have any doubts, consult your doctor or pharmacist. - This medicine has been prescribed only for you and should not be given to others who have the same symptoms, as it may harm them. - If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospectus. See section 4. |
1. What is Rizatriptan Teva 10 mg and what is it used for
2. What you need to know before starting to take Rizatriptan Teva 10 mg
3. How to take Rizatriptan Teva 10 mg
4. Possible adverse effects
5. Storage of Rizatriptan Teva 10 mg
6. Contents of the package and additional information
Rizatriptán Teva belongs to a group of medicines called selective serotonin receptor agonists 5-HT1B/1D.
Rizatriptán Teva is used to treat the headaches of migraine attacks in adults.
Rizatriptán Teva treatment:
Reduces the swelling of blood vessels surrounding the brain. This swelling causes the headache of a migraine attack.
Do not take Rizatriptán Teva if
If you are unsure whether any of the above applies to you, talk to your doctor or pharmacist before taking Rizatriptán Teva.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Rizatriptán Teva:
If you take Rizatriptán Teva frequently, this may lead to chronic headache. In such cases, contact your doctor and stop taking Rizatriptán Teva.
Inform your doctor or pharmacist of all your symptoms. Your doctor will decide if you have migraines. You should only take Rizatriptán Teva for a migraine attack. Rizatriptán Teva should not be used to treat other headaches that may be caused by more serious diseases.
Children and adolescents
The use of Rizatriptán Teva in children and adolescents under 18 years of age is not recommended.
Use in patients over 65 years
There are no completed studies to evaluate the safety and efficacy of Rizatriptán Teva in patients over 65 years.
Other medicines and Rizatriptán Teva
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine, including over-the-counter medicines, herbal medicines, and those you take regularly for migraines. This is because Rizatriptán Teva may affect the mechanism of action of some medicines. Other medicines may also affect Rizatriptán Teva.
Do not take Rizatriptán Teva:
The above-mentioned medicines, when taken with Rizatriptán Teva, may increase the risk of adverse reactions.
After taking Rizatriptán Teva, wait at least 6 hours before taking ergotamine-type medications, such as ergotamine, dihydroergotamine, or methysergide.
After taking ergotamine-type medications, wait at least 24 hours before taking Rizatriptán Teva.
Ask your doctor about the instructions and risks of taking Rizatriptán Teva:
Rizatriptán Teva with food and drinks
Rizatriptán Teva may take longer to take effect if taken after meals. Although it is better to take it on an empty stomach, you can still take it even if you have eaten.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
The available data on the safety of rizatriptan when used during the first three months of pregnancy do not indicate an increased risk of birth defects.The safety of Rizatriptán Teva for the fetus when taken by a pregnant woman after the first three months of pregnancy is unknown.
If you are breastfeeding, you can postpone breastfeeding for 12 hours after treatment to avoid exposing your baby.
Driving and operating machinery
After taking Rizatriptán Teva, you may feel drowsiness or dizziness. If this occurs, do not drive or use tools or machinery.
Rizatriptán Teva contains lactose
If your doctor has told you that you have a certain sugar intolerance, consult your doctor before taking this medicine.
Rizatriptán Teva contains aspartame (E951)
This medicine contains 2.0 mg of aspartame per buccal dispersible tablet.
Aspartame contains a source of phenylalanine that may be harmful in the case of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it correctly.
Rizatriptán Teva contains benzoate
This medicine contains 4.5 mg of benzoate (as rizatriptan benzoate) per buccal dispersible tablet.
Rizatriptán Teva contains sodium
This medicine contains 23 mg of sodium (1 mmol) per buccal dispersible tablet; this is essentially "sodium-free".
Rizatriptan Teva is used to treat migraine attacks. Take Rizatriptan Teva as soon as possible once your migraine headache has started. Do not use it to prevent a migraine attack.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The usual dose is 10 mg.
If you are currently taking propranolol or have kidney or liver problems, you must use a dose of 5 mg of rizatriptan. You must wait at least 2 hours between the intake of propranolol and rizatriptan up to a maximum of 2 doses in a 24-hour period.
How to administer Rizatriptan Teva
Rizatriptan Teva is a buccal disintegrating tablet that dissolves in the mouth.
The buccal disintegrating tablet can be used in situations where there are no liquids available, or to avoid nausea and vomiting that may accompany the ingestion of tablets with liquids.
Do not handle the tablets with wet hands as the buccal disintegrating tablets can break.
1. Hold the blister strip by the edges and separate one blister from the rest of the strip along the perforations.
2. Carefully separate the back part.
3. Gently push the tablet outwards.
4. Place the tablet on your tongue. It will dissolve directly in the mouth, and you can swallow easily.
If the migraine reappears in 24 hours
In some patients, migraine symptoms may reappear within a 24-hour period. If your migraine reappears, you can take an additional dose of Rizatriptan Teva. You must always wait at least 2 hours between doses.
If after 2 hours you still have a migraine
If you do not respond to the first dose of Rizatriptan Teva during an attack, do not take a second dose of Rizatriptan Teva for the same attack.
However, it is still likely that you will respond to Rizatriptan Teva during the next attack.
Do not take more than 2 doses of Rizatriptan Teva in a 24-hour period (for example, do not take more than 2 buccal disintegrating tablets of 5 mg or 2 buccal disintegrating tablets of 10 mg in a 24-hour period). Always wait at least 2 hours between doses.
If your condition worsens, seek medical attention.
If you take more Rizatriptan Teva than you should
If you take more Rizatriptan Teva than you should, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 915 620 420. Bring the medication packaging with you.
The signs of overdose may include dizziness, numbness, vomiting, fainting, and slow heart rate.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. The following side effects may occur with this medicine.
In studies in adults, the side effects reported most frequently were dizziness, drowsiness, and fatigue.
Frequent::may affect up to 1 in 10 people
Infrequent::may affect up to 1 in 100 people
Rare::may affect up to 1 in 1,000 people
Unknown::cannot be estimated from available data
Report any symptoms of allergic reaction, serotonin syndrome, heart attack, or stroke to your doctor immediately.
Also, inform your doctor if you experience any symptoms that suggest an allergic reaction (such as rash or itching) after taking Rizatriptán Teva.
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
Medications should not be disposed of through drains or trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Rizatriptan Teva 10 mg Bucodispersable Tablets Composition
Appearance of the Product and Contents of the Package
Rizatriptan Teva 10 mg Bucodispersable Tablets: are white to off-white, round, smooth, beveled-edge tablets, engraved with ‘IZ’ on one side and ‘10’ on the other side.
Package sizes: 2, 3, 6, 12, 18, 28, or 30 bucodispersable tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Responsible Manufacturer
Marketing Authorization Holder
Teva Pharma, S.L.U.
C/Anabel Segura 11, Edificio Albatros B, 1st floor
28108 Alcobendas, Madrid
Spain
Responsible Manufacturer
TEVA Pharmaceutical Works Private Limited Company
Pallagi út 13, 4042 Debrecen
Hungary
or
Pharmachemie BV
Swensweg 5, 2031 GA Haarlem
Netherlands
or
Teva Operations Poland Sp. z.o.o.
ul. Mogilska 80
31-546 Krakow
Poland
or
Merckle GmbH
Ludwig-Merckle-Straße 3
89143 Blaubeuren
Germany
This medicine is authorized in the member states of the European Economic Area with the following names:
France:-Rizatriptan Teva 10 mg, orodispersible tablet
Germany:-Rizatriptan-ratiopharm 10 mg Melting tablets
Italy:-Rizatriptan Teva 10 mg Compresse Orodispersibili
Netherlands:-Rizatriptan disp 10 mg Teva, orodispergeerbare tablets
Spain:-Rizatriptán Teva 10 mg bucodispersable tablets EFG
Last review date of this leaflet: July 2024
More detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.